ArticleScientific reports2025
Prospective changes in lipocalin-2 and adipocytokines among adults with obesity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bone‑origin repair in diabetic foot ulcers: Mechanisms of callus formation and endocrine effects in healing (Review).International journal of molecular medicine · 2026Review
- Adipokine profiles and genetic variants of leptin receptor, adiponectin, and ghrelin pathways in obesity: prospective 12-month outcomes after bariatric interventions.Frontiers in endocrinology · 2026Observational
- Adipokines and Vascular Modulators in CKM: Emerging Biomarkers as Diagnostic and Therapeutic Targets.International journal of molecular sciences · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Obesity is a significant health concern which can lead to chronic conditions such as heart disease, type 2 diabetes, and cancer. We investigated the impact of obesity on the levels of circulating serum Lipocalin-2 and adipocytokines. A total of 80 consenting participants (50% females) aged 18-60 were enrolled and divided into standard (Group 1) and obese (Group 2) based on their height, weight, age, and body mass index. Changes in LCN-2, adipokines, and inflammatory markers in adults with obesity who took part in a 12-month lifestyle modification program were monitored. The study found that in normal-weight follow-up participants, LCN-2 was positively associated with resistin (R = 0.69, P < 0.001). In the obese group (N = 41), the circulating LCN-2 concentration was positively correlated with the resistin (R = 0.87, P < 0.001) and adiponectin (R = 0.54, P = 0.001). This study highlights the strong associations between circulating LCN-2 and key adipocytokines, particularly in individuals with obesity, underscoring the biomarker's potential role in metabolic dysregulation. The study emphasizes the need for customized interventions and individualized healthcare approaches considering the heterogenous effects of obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.